RxDoctor Payments Data

James Lacotte

Corneal and Contact Management · Madison, NJNPI 1215164991

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Alcon at 33.1% of the total.

$1,553in general payments, 2019–2025

Across 83 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$514
  • Biotissue Holdings Inc.$251
  • Coopervision Inc.$167
  • Johnson & Johnson Vision Care, Inc.$151
  • Bausch & Lomb Americas Inc.$106
  • Dompe US, Inc.$86
  • plus $278 from 7 others

What the payments were for

  • Food & beverage$1,553100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,553 in reported general payments places this provider in the 55th percentile of 45 corneal and contact management providers in New Jersey.

See all corneal and contact management providers in New Jersey

Medicare billing

Part B allowed, 2024
$56,610
Medicare patients
226
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost95$732
Timolol Maleate53$331
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha20$197

Paid to pharmacies, not to this prescriber.

Other corneal and contact management in Madison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →